Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity‐matched cohort study
This large-scale propensity-matched retrospective cohort study suggests a favourable safety profile of dupilumab during pregnancy. Given the difficulties of prospective studies during pregnancy, it provides valuable insights, though further studies are needed to confirm these findings and explore causal relationships.
Authors
- Andreas Recke (ORCID: https://orcid.org/0000-0002-7674-1804)
- Ralf Joachim Ludwig (ORCID: https://orcid.org/0000-0002-1394-1737)
- Henner Zirpel (ORCID: https://orcid.org/0000-0003-0053-4312)
- Evelyn Gaffal (ORCID: https://orcid.org/0000-0002-4639-9841)
- Eva Lotta Moderegger
- Katja Bieber (ORCID: https://orcid.org/0000-0002-3855-6683)
- Khalaf Kridin (ORCID: https://orcid.org/0000-0001-9971-9151)
- Artem Vorobyev (ORCID: https://orcid.org/0000-0002-1542-0732)
- Diamant Thaçi (ORCID: https://orcid.org/0000-0001-8513-550X)
- Sophie L Preuß (ORCID: https://orcid.org/0000-0003-0661-7573)
Institutions
- Bar-Ilan University (IL)
- University Hospital Schleswig-Holstein (DE)
- Poriya Medical Center (IL)
- University of Lübeck (DE)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1111/jdv.20670
- Citations
- 9
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 16.91
Funders
- Deutsche Forschungsgemeinschaft